Published in Am J Surg Pathol on October 01, 2010
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell (2013) 2.81
Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A (2011) 2.71
Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin (2011) 2.57
The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 2.47
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol (2014) 2.19
High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A (2012) 2.03
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol (2012) 1.34
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer (2011) 1.30
Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res (2012) 1.30
Ovarian Cancer Is an Imported Disease: Fact or Fiction? Curr Obstet Gynecol Rep (2012) 1.23
Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol (2011) 1.15
Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol (2012) 1.13
The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention". Clin Obstet Gynecol (2012) 1.13
Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int (2014) 1.11
Stem-like epithelial cells are concentrated in the distal end of the fallopian tube: a site for injury and serous cancer initiation. Stem Cells (2012) 1.09
Coming into focus: the nonovarian origins of ovarian cancer. Ann Oncol (2013) 1.07
Through the glass darkly: intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J Pathol (2013) 1.06
Primary culture and immortalization of human fallopian tube secretory epithelial cells. Nat Protoc (2012) 1.03
BRCA and Early Events in the Development of Serous Ovarian Cancer. Front Oncol (2014) 1.03
Fallopian tube removal: "stic-ing" it to ovarian cancer: what is the utility of prophylactic tubal removal? Curr Oncol (2013) 1.02
Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol (2012) 0.99
Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97
The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol (2012) 0.96
Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol (2013) 0.95
The molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube origin. Int J Mol Sci (2013) 0.92
Precursors of ovarian cancer in the fallopian tube: serous tubal intraepithelial carcinoma--an update. J Obstet Gynaecol Res (2014) 0.92
Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas. Int J Clin Exp Pathol (2012) 0.91
Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues. Proc Natl Acad Sci U S A (2016) 0.91
It's Totally Tubular…Riding The New Wave of Ovarian Cancer Research. Cancer Res (2015) 0.90
IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis. J Exp Clin Cancer Res (2014) 0.88
Characterization of the immune cell repertoire in the normal fallopian tube. Int J Gynecol Pathol (2014) 0.88
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Int J Gynecol Pathol (2016) 0.88
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol (2015) 0.87
Pathobiology of ovarian carcinomas. Chin J Cancer (2015) 0.87
Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov (2016) 0.87
Ovary and fimbrial stem cells: biology, niche and cancer origins. Nat Rev Mol Cell Biol (2015) 0.86
CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol (2016) 0.86
Fallopian tube prolapse after hysterectomy: a systematic review. PLoS One (2013) 0.84
Tubal ligation and incidence of 26 site-specific cancers in the Million Women Study. Br J Cancer (2016) 0.84
An orthotopic model of platinum-sensitive high grade serous fallopian tube carcinoma. Int J Clin Exp Pathol (2011) 0.84
Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract (2015) 0.84
The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. Endocrinology (2015) 0.84
Prophylactic bilateral salpingectomy (PBS) to reduce ovarian cancer risk incorporated in standard premenopausal hysterectomy: complications and re-operation rate. J Cancer Res Clin Oncol (2014) 0.82
Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. Front Oncol (2014) 0.82
Macrophage capping protein CapG is a putative oncogene involved in migration and invasiveness in ovarian carcinoma. Biomed Res Int (2014) 0.81
Primary peritoneal serous carcinoma with signet ring cells. Gynecol Oncol Case Rep (2011) 0.80
Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer. Geburtshilfe Frauenheilkd (2015) 0.80
PAX8 expression in ovarian surface epithelial cells. Hum Pathol (2015) 0.79
Salpingectomy as standard at hysterectomy? A Danish cohort study, 1977-2010. BMJ Open (2013) 0.79
Early preinvasive lesions in ovarian cancer. Biomed Res Int (2014) 0.79
MUC1 positive, Kras and Pten driven mouse gynecologic tumors replicate human tumors and vary in survival and nuclear grade based on anatomical location. PLoS One (2014) 0.78
Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol (2012) 0.78
Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol (2014) 0.78
Ovarian cancer stroma: pathophysiology and the roles in cancer development. Cancers (Basel) (2012) 0.77
Endometrial Cancer: Comparison of Patients with Synchronous Primary Carcinoma of the Endometrium and Ovary vs. Endometrial Carcinoma with Ovarian Metastases. Geburtshilfe Frauenheilkd (2012) 0.77
Nonovarian origins of ovarian cancer. Proc Natl Acad Sci U S A (2012) 0.77
GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012. Clin Transl Oncol (2013) 0.76
Ovarian cancer risk reduction through opportunistic salpingectomy. J Gynecol Oncol (2015) 0.76
Serous tubal intraepithelial neoplasia: the concept and its application. Mod Pathol (2017) 0.76
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract (2015) 0.76
Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer. J Ovarian Res (2016) 0.76
Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight (2016) 0.76
Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence. Cancer Prev Res (Phila) (2016) 0.76
Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases. Diagn Pathol (2016) 0.75
A feasibility study to identify proteins in the residual Pap test fluid of women with normal cytology by mass spectrometry-based proteomics. Clin Proteomics (2014) 0.75
Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar. Geburtshilfe Frauenheilkd (2015) 0.75
Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol (2016) 0.75
Stromal alterations in ovarian cancers via wavelength dependent Second Harmonic Generation microscopy and optical scattering. BMC Cancer (2017) 0.75
Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. Case Rep Pathol (2016) 0.75
Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy. Cancer Cell Int (2016) 0.75
Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy. Obstet Gynecol (2014) 0.75
High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect Agent Cancer (2016) 0.75
Microscopic lesions of fallopian tubes in endometrioid carcinoma of the endometrium: How effective are the macroscopic tubal sampling techniques? J Gynecol Oncol (2013) 0.75
Impact and mechanistic role of oral contraceptive pills on the number and epithelial type of ovarian cortical inclusion cysts; a clinicopathology and immunohistochemical study. Diagn Pathol (2016) 0.75
Risk-reducing salpingectomy: Let us be opportunistic. Cancer (2017) 0.75
Ovarian cancer and the pelvic floor surgeon: the case for prophylactic bilateral salpingectomy during POP surgery. Int Urogynecol J (2012) 0.75
[Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis]. Pathologe (2011) 0.75
Increased RHAMM expression relates to ovarian cancer progression. J Ovarian Res (2017) 0.75
BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol (2017) 0.75
Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun (2017) 0.75
Serous Tubal Carcinogenesis: The Recent Concept of Origin of Ovarian, Primary Peritoneal and Fallopian Tube High-Grade Serous Carcinoma. J Obstet Gynaecol India (2017) 0.75
LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions. Mod Pathol (2017) 0.75
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol (2004) 6.20
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A (2002) 3.46
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 3.22
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol (2004) 2.95
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clin Cancer Res (2004) 2.84
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol (2002) 2.73
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol (2008) 2.60
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol (2012) 2.27
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol (2002) 2.18
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol (2003) 2.06
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol (2010) 2.05
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol (2011) 2.03
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol (2011) 2.02
Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer (2008) 2.01
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol (2005) 1.94
Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol (2004) 1.92
The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol (2006) 1.91
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control (2008) 1.89
Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res (2005) 1.80
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol (2009) 1.71
Amplicon profiles in ovarian serous carcinomas. Int J Cancer (2007) 1.70
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol (2007) 1.70
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res (2004) 1.66
Methylated genes in breast cancer: associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol Ther (2011) 1.62
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol (2009) 1.62
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol (2003) 1.58
Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol (2011) 1.56
Principle and applications of digital PCR. Expert Rev Mol Diagn (2004) 1.55
Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res (2005) 1.55
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52
Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol (2003) 1.47
The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol (2011) 1.47
Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol (2002) 1.46
Distribution of human papillomavirus types 16 and 18 variants in squamous cell carcinomas and adenocarcinomas of the cervix. Cancer Res (2003) 1.46
Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. Obstet Gynecol (2009) 1.45
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol (2010) 1.45